NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Spyre Therapeutics, Inc. SYRE
12 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-155.2M
Growth
—
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -155.2
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2023 · Operating -27348.0% · Net -38238.1%
ROE
FY2025 · ROE -25.2%
Each USD of equity lost 25 cents this year.
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Operating income $B | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | −0.2 | −0.3 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | 13.76 | −24.86 | −25.02 | −1.52 | −2.45 | −2.13 | −1.80 | −2.22 | −19.21 | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −25.2 | −59.3 | −289.2 | −124.9 | −58.8 | −80.9 | −122.7 | −75.3 | −48.1 | −106.5 | · | · |
| Shares out B | 0.08 | 0.06 | 0.04 | 0.00 | 0.05 | 0.05 | 0.03 | 0.02 | 0.02 | 0.01 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 43 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 33 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014